BIOA vs SYF · rev $9.0M vs rev $11.19B
BioAge Labs, Inc (BIOA) versus SYF (SYF) — a side-by-side from cached financials, not a winner call.
BioAge Labs, Inc (BIOA) is a drug manufacturers - specialty & generic company listed on US.
SYF (SYF) common stock.
Latest reported BIOA revenue for 2025-12-31 was $9.0M. Net income was -$80.6M. BIOA currently screens at market cap $697.9M.
Latest reported SYF revenue for 2026-06-30 was $11.19B. Net income was $1.69B. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. SYF currently screens at market cap $0.
BIOA currently screens at market cap $697.9M. SYF currently screens at market cap $0.
Not investment advice. Open the BIOA and SYF stock pages for the full models.
Not investment advice.